Akari Therapeutics (STU:CLA1) Cyclically Adjusted Book per Share: €7,353.76 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CLA1 Akari Therapeutics PLC STU:CLA1
30 GF Score
Price €134.40
View Full Analysis

What is Akari Therapeutics Cyclically Adjusted Book per Share?

Akari Therapeutics STU:CLA1 30 Cyclically Adjusted Book per Share is €7,353.76 as of Jun. 2026. GuruFocus rates STU:CLA1 with a GF Score™ of 30/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Akari Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was €9.223. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €7,353.76 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Akari Therapeutics's average Cyclically Adjusted Book Growth Rate was -26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-25), Akari Therapeutics's current stock price is €134.40. Akari Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €7,353.76. Akari Therapeutics's Cyclically Adjusted PB Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Akari Therapeutics was 0.01. The lowest was 0.00. And the median was 0.00.


Akari Therapeutics  (STU:CLA1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Akari Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=134.40/7353.76
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Akari Therapeutics was 0.01. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Akari Therapeutics Cyclically Adjusted Book per Share Related Terms


Akari Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Akari Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akari Therapeutics Cyclically Adjusted Book per Share Chart

Akari Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1,427.01 2,886.35 8,965.39

Akari Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,582.25 2,898.32 8,965.39 17,401.02 7,353.76

STU:CLA1 vs MBRX, INTI, TPST: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Akari Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akari Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:CLA1
30GF Score
Akari Therapeutics PLC STU:CLA1
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akari Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akari Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=9.223/333.9520*333.9520
=9.223

Current CPI (Jun. 2026) = 333.9520.

Akari Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 2,408.000 241.018 3,336.499
201609 2,437.800 241.428 3,372.054
201612 2,155.333 241.432 2,981.286
201703 1,396.000 243.801 1,912.203
201706 1,355.867 244.955 1,848.480
201709 729.467 246.819 986.986
201712 762.895 246.524 1,033.450
201803 696.789 249.554 932.440
201806 388.684 251.989 515.109
201809 270.100 252.439 357.316
201812 136.750 251.233 181.775
201903 54.000 254.202 70.941
201906 -57.810 256.143 -75.371
201909 113.500 256.759 147.623
201912 0.250 256.974 0.325
202003 45.639 258.115 59.048
202006 70.595 257.797 91.449
202009 98.190 260.280 125.983
202012 160.708 260.474 206.043
202103 68.896 264.877 86.863
202106 26.360 271.696 32.400
202109 163.712 274.310 199.307
202112 83.322 278.802 99.804
202203 170.932 287.504 198.547
202206 106.432 296.311 119.952
202212 18.183 296.797 20.459
202303 0.000 301.836 0.000
202306 20.213 305.109 22.124
202309 0.000 307.789 0.000
202312 -1.273 306.746 -1.386
202403 -16.345 312.332 -17.476
202406 -11.316 314.175 -12.028
202409 -19.839 315.301 -21.013
202412 31.923 315.605 33.779
202503 27.860 319.799 29.093
202506 27.239 322.561 28.201
202509 23.717 324.800 24.385
202512 21.371 324.054 22.024
202603 10.864 330.213 10.987
202606 9.223 333.952 9.223

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €7,353.76 mean?
Akari Therapeutics (STU:CLA1) has a Cyclically Adjusted Book per Share of €7,353.76 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Akari Therapeutics and its competitors.
Is Akari Therapeutics' Cyclically Adjusted Book per Share too high?
Akari Therapeutics' current Cyclically Adjusted Book per Share is €7,353.76. Overall, Akari Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Cyclically Adjusted Book per Share compare to MBRX and INTI?
Akari Therapeutics' Cyclically Adjusted Book per Share of €7,353.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Akari Therapeutics and its competitors. Akari Therapeutics's current Cyclically Adjusted Book per Share is €7,353.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (STU:CLA1) has a current Cyclically Adjusted Book per Share of €7,353.76. The current Cyclically Adjusted Book per Share is €7,353.76. Akari Therapeutics' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Akari Therapeutics (STU:CLA1), the current Cyclically Adjusted Book per Share is €7,353.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Other Exchanges AKTX:USA
Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
30GF Score

Get the complete analysis for STU:CLA1

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€134.40
Price